论文部分内容阅读
目的:探讨奥扎格雷联合吡拉西坦对急性脑梗死患者神经功能缺损的疗效。方法:选取200例急性脑梗死患者,按照入院时间顺序不同分为两组,奥扎格雷组(92例)静脉滴注奥扎格雷钠注射液治疗,联合用药组(108例)静脉滴注奥扎格雷钠注射液联合吡拉西坦注射液治疗。观察并记录两组治疗前治疗后神经功能缺损,疗效,日常生活能力及随访1个月期间不良反应发生情况,评价奥扎格雷联合吡拉西坦对急性脑梗死患者神经功能缺损的疗效。结果:与治疗前相比,治疗后两组ESS评分均明显增加(P<0.05),且联合用药组在治疗后各时间段均明显高于奥扎格雷组(P<0.05)。治疗后14 d,联合用药组有效率为76.8%,奥扎格雷组为60.9%,联合用药组有效率明显高于奥扎格雷组;治疗后两组Barthel评分明显高于治疗前(P<0.05),且联合用药组高于奥扎格雷组(P<0.05)。随访1个月期间,两组不良反应率比较,差异没有统计学意义(P>0.05)。结论:奥扎格雷联合吡拉西坦能明显改善急性脑梗死患者神经功能缺损情况,提高患者生活能力,用药安全,值得临床推广使用。
Objective: To investigate the efficacy of ozagrel in combination with piracetam on neurological deficits in patients with acute cerebral infarction. Methods: A total of 200 patients with acute cerebral infarction were enrolled and divided into two groups according to the order of admission. Ozagrel group (n = 92) received intravenous injection of ozagrel sodium, and the combination group (n = 108) Zagre sodium injection combined with piracetam injection. The neurological deficit, efficacy, daily living ability and incidence of adverse reactions in one month after follow-up were observed and recorded before treatment, and the effect of ozagrel and piracetam on neurological deficits in patients with acute cerebral infarction was evaluated. Results: Compared with those before treatment, ESS score of both groups increased significantly after treatment (P <0.05), and the combination group was significantly higher than that of ozagrel group after treatment (P <0.05). On the 14th day after treatment, the effective rate was 76.8% in the combination group and 60.9% in the ozagrel group, and the effective rate in the combination group was significantly higher than that in the ozagrel group. The Barthel scores of the two groups were significantly higher than those before treatment (P <0.05 ), And the combination group was higher than the ozagrel group (P <0.05). During one month follow-up, there was no significant difference between the two groups in adverse reaction rate (P> 0.05). Conclusion: Ozagrel combined with piracetam can significantly improve neurological deficits in patients with acute cerebral infarction, improve patients’ ability to live, medication safety, and worthy of clinical promotion and use.